August 15, 2017
Using fragments of circulating tumor DNA in blood, University of California San Diego School of Medicine researchers were able to identify theoretically targetable genetic alterations in 66 percent of patients with cancer of unknown primary (CUP), a rare disease with seven to 12 cases per 100,000 people each year.
December 14, 2011
…conference for teachers, parents, therapists, and school administrators called Bridging the Hearts & Minds of Youth. The two-day conference is designed to familiarize and train attendees with the ways in which mindfulness is being taught to children and teens in a variety of settings. The goal is to teach mindfulness…
August 2, 2022
Researchers report that a gene therapy approach, developed at UC San Diego measurably delayed disease onset in humanized mouse and rat models of familial ALS, an inherited form of the disease that runs in families.
November 19, 2012
For work toward a safer approach to treating cancer, electrical engineering Ph.D. student Inanc Ortac from the University of California, San Diego has won first prize in the graduate student category at the 2012 Collegiate Inventors Competition.
March 19, 2013
From Saturday, April 6 to Sunday April 7, the Center for Integrative Medicine at University of California, San Diego School of Medicine is hosting a landmark conference on integrative oncology. Participants will learn what can be done to foster an “anti-cancer” diet and lifestyle to help rectify health imbalances and…
May 3, 2018
…basic and advanced imaging, physical therapy and pain management plus infusion and apheresis services. “The Koman family has been remarkably generous to all of us,” said Dr. David A. Brenner, Vice Chancellor of UC San Diego Health Sciences. “Pedal the Cause, the Koman Family Presidential Endowed Chair, scholarships … in…
July 20, 2017
…cancer stem cells, whose survival abilities often render standard therapies ineffective or short-term.
April 17, 2014
Scientists studying the most common form of inherited mental disability—a genetic disease called “Fragile X syndrome”—have uncovered new details about the cellular processes responsible for the condition that could lead to the development of therapies to restore some of the capabilities lost in affected individuals.
May 13, 2021
…the coordination of complex therapies and the team-based care led by Dr. Joseph A. Califano III, director of the newly named Hanna and Mark Gleiberman Head and Neck Cancer Center at UC San Diego Health. The Gleiberman Head and Neck Cancer Center, led by its director, Joseph A. Califano III,…
September 21, 2020
Moores Cancer Center at UC San Diego Health is using advanced imaging, genomics, personalized medicine and new therapies to treat patients like Brian McCloskey, who has stage IV prostate cancer.
